Komori
Japan Animal Referral Medical Center (6039) · InitiativeAdvanced

Granting Shares to Directors Through Restricted Stock Compensation

First written in FY2018-Q2. 4 of 6 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2026.

6entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2018 – FY20262017: 12018: 120182019: 020192020: 120202021: 020212022: 120222023: 020232024: 120242025: 020252026: 12026
Same theme, other companies
Medium- to Long-Term Incentives Through Equity Compensation Plans for Directors and EmployeesA theme 784 companies write about · 0 as a headwind · 808 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 193 companies compared. The sentences above are computed from all 193.Comparing 200 of the theme's 808 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「2023 advance-delivery plan: 115,000 common shares; continued employment through the vesting date (16 August 2026). 2024 advance-delivery plan: 60,000 common shares; continued employment until the date on which the individual ceases to hold any position specified by the Board of Directors.」

    For the restricted stock compensation plan, the Company disclosed the number of shares covered by the 2023 and 2024 advance-delivery plans and the vesting periods subject to continued employment.
  2. FY2024AdvancedAnnual report

    「Other (disposal of treasury shares under the restricted stock compensation plan) 23,000 39,045,350」

    The Company disposed of 23,000 treasury shares as restricted stock compensation under the 2023 advance-delivery plan and disclosed operation of the plan through August 2026, subject to continued employment.
  3. FY2022AdvancedAnnual report

    「The Company has introduced a restricted stock compensation plan as non-monetary compensation to provide its directors with incentives to achieve sustained growth in corporate value and to further promote value sharing between directors and shareholders. To provide incentives for sustained growth in corporate value and achieve the sharing of shareholder value, which are the purposes of introducing the plan, the transfer restriction period is 3 to 5 years. The total number of shares delivered under the plan is limited to 80,000 shares per year and ¥80 million per year for eligible directors.」

    For the restricted stock compensation plan, the Company disclosed its purpose, a transfer restriction period of 3 to 5 years, and annual limits of 80,000 shares and ¥80 million. It recognized ¥17.983 million as an expense in the fiscal year ended March 2022.
  4. FY2021-Q2AdvancedAnnual report

    「In addition to the disposal of 8,000 treasury shares upon the exercise of stock acquisition rights and the disposal of 25,000 treasury shares as restricted stock compensation based on a resolution of the Board of Directors held on 6 August 2020, treasury shares decreased by ¥53.303 million (33,000 shares).」

    The Company disposed of 25,000 treasury shares as restricted stock compensation, implementing an additional existing stock compensation measure.
  5. FY2018AchievedAnnual report

    「17 August 2017 (Note) 7 Common shares 35,000 Common shares 2,385,700 37,240 372,875 37,240 272,875 (Note) 7. The increase resulted from the issuance of new shares under the restricted stock compensation plan.」

    The full-year materials confirm the implementation of a plan under which 35,000 new shares were issued as restricted stock compensation and allocated to 3 directors.
  6. FY2018-Q2First statedAnnual report

    「Of the shares issued, 35,000 shares were issued through an in-kind contribution of monetary compensation claims totaling ¥74.48 million. The increase resulted from the issuance of new shares under the restricted stock compensation plan. Issue price: ¥2,128 Amount incorporated into capital: ¥1,064 Allottees: 3 directors of the Company」

    During the quarter, the Company issued 35,000 shares as restricted stock compensation through an in-kind contribution of monetary compensation claims and allocated them to 3 directors.
Moved together

"Providing State-of-the-Art Veterinary Care and Achieving Qualitative Growth" moved the same way as this thread, in the same document, in 5 of its 6 moves.

544444★123456
  1. ★This thread
  2. 1Providing State-of-the-Art Veterinary Care and Achieving Qualitative Growth5×
  3. 2Expansion of secondary-care facilities in major cities nationwide4×
  4. 3Expansion and strengthening of the affiliated-hospital network4×
  5. 4Developing and Securing Outstanding Talent4×
  6. 5Target to increase the number of first-time consultations as the most important management metric4×
  7. 6Dilution of Share Value from Stock Options4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Japan Animal Referral Medical Center yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.